ConvaTec, the medical products and technologies company that entered the FTSE 100 after becoming the biggest London flotation of 2016, has agreed to acquire Woodbury Holdings, a US distributor of incontinence and catheter-related supplies for $120.5m.
Woodbury, which provides items including incontinence and catheter products, has national distribution across the US, delivering directly to customers at home, reports Sarah Neville, Global Pharmaceuticals Editor.
ConvaTec said the acquisition from MTS Health Investors would create a new home distribution business unit for catheter and incontinence related products. It will take in US distribution companies 180 Medical, Symbius Medical, South Shore Medical Supply, Wilmington Medical Supply and Woodbury Health Products.
Paul Moraviec, ConvaTec chief executive, said: “The addition of Woodbury contributes to our growth strategy for the Continence & Critical Care Franchise and builds on the success of our 180 Medical business, which we acquired in 2012.” 180 Medical was the largest retailer of intermittent catheters in the US, he said.
The addition of Woodbury would provide “further breadth and reach to our new home distribution group and further consolidate our leading position in this market, expand customer relationships and provide greater choice direct to US consumers,” he added. Woodbury’s senior management team will remain with the company.
Source: Financial Times
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
